 SAN DIEGO, Aug. 26, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento, a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain non-opioid treatments, autoimmune disease and COVID-19, today announced promising preclinical results for its mRNA vaccine against SARS-CoV-2. STI-mRNA is comprised of proprietary designer Spike-encoding mRNAs to elicit cellular and humoral immunity against the early WA-1 virus as well as the predominant and emerging variants of concern VOCs, including Alpha, Beta, Gamma, Delta, and Lambda. 